Sort
25,944 grants matching “neurodegeneration”
HABS-HD - Core D - Omics Core
$7,902,235Leigh A Johnson · University Of North Texas Hlth Sci Ctr · U19 · FY2025 · AG
A randomized, placebo-controlled, double-blind study to evaluate safety and efficacy of NDX-1017 treatment in Alzheimer's dementia patients
$7,811,344Xue Hua · Athira Pharma, Inc. · R01 · FY2020 · AG
Early Onset Alzheimer's Disease Consortium
$7,654,317Liana G Apostolova · Indiana University Indianapolis · R56 · FY2017 · AG
Modernization of the Yale PET Core
$7,651,943Georges El Fakhri · Yale University · C06 · FY2025 · OD
Topographic, cell type and molecular pathway characterization ofAlzheimer's disease using single cell transcriptomics and epigenomics
$7,490,446Ed Lein · Allen Institute · U19 · FY2022 · AG
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
$7,047,943Reisa A. Sperling · Brigham And Women'S Hospital · R01 · FY2019 · AG
Dysfunctional lipid metabolism and peroxidation in chronic pain and neurodegeneration
$7,042,784Christopher Ramsden · National Institute On Aging · ZIA · FY2022 · AG
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
$6,944,873Reisa A. Sperling · Brigham And Women'S Hospital · R01 · FY2021 · AG
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
$6,943,250Reisa A. Sperling · Brigham And Women'S Hospital · R01 · FY2022 · AG
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
$6,941,600Reisa A. Sperling · Brigham And Women'S Hospital · R01 · FY2023 · AG
The role of astrogliosis in aging and the pathological and clinical progression of Alzheimer's Disease
$6,932,984Ann D. Cohen · University Of Pittsburgh At Pittsburgh · P01 · FY2023 · AG
The role of astrogliosis in aging and the pathological and clinical progression of Alzheimer's Disease
$6,909,110Ann D. Cohen · University Of Pittsburgh At Pittsburgh · P01 · FY2022 · AG
Clinical & biological signatures of post-traumatic neurodegeneration: Toward in vivo diagnosis of the late effects of TBI.
$6,907,906Kristen Dams-O'Connor · Icahn School Of Medicine At Mount Sinai · RF1 · FY2019 · NS
Alzheimer's Disease Sequencing Project Phenotype Harmonization Consortium
$6,835,050Timothy J Hohman · Vanderbilt University Medical Center · U24 · FY2021 · AG
Dominantly Inherited Alzheimer Network
$6,724,923Randall J Bateman · Washington University · U19 · FY2021 · AG
The role of astrogliosis in aging and the pathological and clinical progression of Alzheimer's Disease
$6,703,737Ann D. Cohen · University Of Pittsburgh At Pittsburgh · P01 · FY2024 · AG
ARIC Neurocognitive Study (ARIC-NCS) Renewal 2023-2028
$6,700,232Josef Coresh · New York University School Of Medicine · U01 · FY2024 · HL
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Mild-to-Moderate Dementia with Lewy Bodies (DLB)
$6,682,055John Alam · Eip Pharma, Inc. · R01 · FY2023 · AG
Core D: Neuroimaging Core
$6,650,768Bradley T Christian · University Of Pittsburgh At Pittsburgh · U19 · FY2023 · AG
Neurocognitive aging, MCI and Alzheimer's disease DNA methylation among diverse Latinos
$6,630,354Hector M Gonzalez · University Of California, San Diego · RF1 · FY2019 · AG
ARIC Neurocognitive Study (ARIC-NCS) Renewal 2023-2028
$6,605,599Josef Coresh · New York University School Of Medicine · U01 · FY2025 · HL
Einstein Aging Study
$6,602,838Carol A Derby · Albert Einstein College Of Medicine · P01 · FY2022 · AG
Dominantly Inherited Alzheimer Network
$6,556,948Randall J Bateman · Washington University · U19 · FY2022 · AG
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study
$6,500,000Susan Abushakra · Alzheon, Inc. · R01 · FY2023 · AG
APOE in the Predisposition to, Protection from and Prevention of Alzheimer's Disease
$6,488,333Eric M Reiman · Banner Health · R01 · FY2022 · AG